[go: up one dir, main page]

WO2009060452A3 - Procédés et compositions pour le traitement de cristallisation de cholestérol biliaire et d'affections connexes - Google Patents

Procédés et compositions pour le traitement de cristallisation de cholestérol biliaire et d'affections connexes Download PDF

Info

Publication number
WO2009060452A3
WO2009060452A3 PCT/IL2008/001467 IL2008001467W WO2009060452A3 WO 2009060452 A3 WO2009060452 A3 WO 2009060452A3 IL 2008001467 W IL2008001467 W IL 2008001467W WO 2009060452 A3 WO2009060452 A3 WO 2009060452A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
related conditions
biliary cholesterol
cholesterol crystallization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2008/001467
Other languages
English (en)
Other versions
WO2009060452A2 (fr
Inventor
Tuvia Gilat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galmed International Ltd
Original Assignee
Galmed International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed International Ltd filed Critical Galmed International Ltd
Publication of WO2009060452A2 publication Critical patent/WO2009060452A2/fr
Publication of WO2009060452A3 publication Critical patent/WO2009060452A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne le traitement d'affections liées à la cristallisation de cholestérol biliaire, particulièrement l'administration d'inhibiteurs de stéaroyl coenzyme A désaturase 1, sachant que l'inhibiteur de l'activité enzymatique de SCD1 n'est pas un conjugué d'acide biliaire et d'acide gras (FABAC).
PCT/IL2008/001467 2007-11-08 2008-11-06 Procédés et compositions pour le traitement de cristallisation de cholestérol biliaire et d'affections connexes Ceased WO2009060452A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98629607P 2007-11-08 2007-11-08
US60/986,296 2007-11-08

Publications (2)

Publication Number Publication Date
WO2009060452A2 WO2009060452A2 (fr) 2009-05-14
WO2009060452A3 true WO2009060452A3 (fr) 2009-08-06

Family

ID=40343556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/001467 Ceased WO2009060452A2 (fr) 2007-11-08 2008-11-06 Procédés et compositions pour le traitement de cristallisation de cholestérol biliaire et d'affections connexes

Country Status (1)

Country Link
WO (1) WO2009060452A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
CN105611919A (zh) * 2013-08-08 2016-05-25 盖尔德姆疗法有限公司 包含胆汁酸-脂肪酸缀合物的抗痤疮组合物
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60172925A (ja) * 1984-02-17 1985-09-06 Kao Corp 胆石溶解剤
JPS60172922A (ja) * 1984-02-17 1985-09-06 Kao Corp 胆石溶解剤
US4767783A (en) * 1983-08-19 1988-08-30 Kao Corporation Gallstone dissolver
EP0490561A2 (fr) * 1990-12-07 1992-06-17 Scotia Holdings Plc Alimentation
CN1228969A (zh) * 1998-03-18 1999-09-22 许秋菊 一组防治胆石病的药物及鉴别胆石种类方案
WO1999053935A1 (fr) * 1998-04-16 1999-10-28 Ida Development A/S Nouvelles compositions synergiques contenant des composes aromatiques et des terpenoides presents chez alpinia galanga
WO2003075925A1 (fr) * 2002-03-08 2003-09-18 Wisconsin Alumni Research Foundation Procedes permettant de reduire la graisse l'adiposite et d'accroitre la masse corporelle maigre en reduisant l'activite de la stearyl-coa desaturase 1
US20060041017A1 (en) * 2004-08-20 2006-02-23 Chopra Raj K Synergistic conjugated linoleic acid (CLA) and carnitine combination

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767783A (en) * 1983-08-19 1988-08-30 Kao Corporation Gallstone dissolver
JPS60172925A (ja) * 1984-02-17 1985-09-06 Kao Corp 胆石溶解剤
JPS60172922A (ja) * 1984-02-17 1985-09-06 Kao Corp 胆石溶解剤
EP0490561A2 (fr) * 1990-12-07 1992-06-17 Scotia Holdings Plc Alimentation
CN1228969A (zh) * 1998-03-18 1999-09-22 许秋菊 一组防治胆石病的药物及鉴别胆石种类方案
WO1999053935A1 (fr) * 1998-04-16 1999-10-28 Ida Development A/S Nouvelles compositions synergiques contenant des composes aromatiques et des terpenoides presents chez alpinia galanga
WO2003075925A1 (fr) * 2002-03-08 2003-09-18 Wisconsin Alumni Research Foundation Procedes permettant de reduire la graisse l'adiposite et d'accroitre la masse corporelle maigre en reduisant l'activite de la stearyl-coa desaturase 1
US20060041017A1 (en) * 2004-08-20 2006-02-23 Chopra Raj K Synergistic conjugated linoleic acid (CLA) and carnitine combination

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AYYAD NARIMAN ET AL: "Prevention of cholesterol cholelithiasis by dietary unsaturated fats in hormone-treated female hamsters", LIPIDS, CHAMPAIGN, IL, US, vol. 31, no. 7, 1 January 1996 (1996-01-01), pages 721 - 727, XP008102046, ISSN: 0024-4201 *
DATABASE WPI Week 198542, Derwent World Patents Index; AN 1985-259591, XP002515425 *
DATABASE WPI Week 198542, Derwent World Patents Index; AN 1985-259593, XP002515426 *
DATABASE WPI Week 200002, Derwent World Patents Index; AN 2000-013931, XP002515424 *
KONIKOFF FRED M ET AL: "PREVENTION AND DISSOLUTION OF CHOLESTEROL GALLSTONES BY FATTY ACID BILE ACID CONJUGATES (FABACS) IN RODENTS ARE MEDIATED BY INHIBITION OF STEAROYL COA DESATURASE 1 (SCD1) ACTIVITY IN THE LIVER", 59TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVE R-DISEASES; SAN FRANCISCO, CA, USA; OCTOBER 31 -NOVEMBER 04, 2008,, vol. 48, no. 4, SUPPL S, 4 November 2008 (2008-11-04), pages 653A, XP008101780, Retrieved from the Internet <URL:http://www3.interscience.wiley.com/cgi-bin/issn?DESCRIPTOR=PRINTISSN& VALUE=0270-9139> [retrieved on 20081104] *
SMITH S B ET AL: "Conjugated linoleic acid depresses the DELTA9 desaturase index and stearoyl coenzyme A desaturase enzyme activity in porcine subcutaneous adipose tissue", JOURNAL OF ANIMAL SCIENCE, vol. 80, no. 8, August 2002 (2002-08-01), pages 2110 - 2115, XP002515423, ISSN: 0021-8812 *
VALEILLE K ET AL: "LIPID ATHEROGENIC RISK MARKERS CAN BE MORE FAVOURABLY INFLUENCED BY THE CIS-9,TRANS-11-OCTADECADIENOATE ISOMER THAN A CONJUGATED LINOLEIC ACID MIXTURE OR FISH OIL IN HAMSTERS", BRITISH JOURNAL OF NUTRITION, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 91, no. 2, 1 January 2004 (2004-01-01), pages 191 - 199, XP003019713, ISSN: 0007-1145 *

Also Published As

Publication number Publication date
WO2009060452A2 (fr) 2009-05-14

Similar Documents

Publication Publication Date Title
WO2010035219A3 (fr) Dérivés de pyrazolopyridine utilisés comme inhibiteurs de la nadph oxydase
WO2009079412A3 (fr) Inhibiteurs de transcriptase inverse
UA102574C2 (ru) 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы
WO2010074588A8 (fr) Composés pharmaceutiques
WO2007137107A3 (fr) Inhibiteurs de l&#39;enzyme diacylglycerol o-acyltransférase de type 1
WO2009089263A3 (fr) Nouvelles compositions et procédés d&#39;utilisation
PH12012500904A1 (en) Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
WO2007008586A3 (fr) Acides gras polyinsatures pour le traitement de la demence et d&#39;etats predementiels
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2007137066A3 (fr) Inhibiteurs hétérocycliques de la déshydrogénase du stéroïde hydroxyle 11-b de type 1 et leurs procédés d&#39;utilisation
EP2573069A3 (fr) Inhibiteurs d&#39;histone désacétylase et leurs promédicaments
WO2012065958A9 (fr) Procédé de traitement d&#39;une néphropathie induite par les produits de contraste
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
WO2010046445A3 (fr) Dérivées d’urée de nortropanes substitués, médicaments contenant de tels composés et leur utilisation
MX2009011754A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
WO2009048249A3 (fr) Composition destinée à prévenir ou à traiter des troubles du métabolisme lipidique contenant de la fucoxanthine ou un extrait de plante marine la contenant
WO2009102428A3 (fr) INHIBITEURS 1,3-OXAZEPAN-2-ONE ET 1,3-DIAZEPAN-2-ONE DE LA 11β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE (TYPE1)
MX2010003449A (es) Derivado de quinolona.
WO2008024139A3 (fr) Inhibiteurs d&#39;hydrolase des amides d&#39;acides gras
WO2008076427A3 (fr) Composés de naphtalénone présentant une activité inhibititrice de prolyle hydroxylase, compositions et utilisations de ceux-ci
NZ596228A (en) Compositions and methods for the treatment of inflammation
PL2173173T3 (pl) Podstawione pochodne 6-anilinopuryny jako inhibitory oksydazy/dehydrogenazy cytokinin i preparaty zawierające te pochodne
ZA200810862B (en) Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11B-HSD 1)
WO2008034796A3 (fr) Triazoles thérapeutiquement actives et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08847545

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08847545

Country of ref document: EP

Kind code of ref document: A2